- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03888989
Response to Influenza Vaccine During Pregnancy (FLU-PG)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I mechanistic study of licensed influenza vaccines with up to 50 pregnant female volunteers, 18-49 years of age. Investigator intends to collect blood from pregnant women and then from the same women a year later when they are not pregnant after routine seasonal influenza vaccination. By studying the blood of immunized pregnant women and in these same women after pregnancy, the investigator will gain a better understanding of the immune response to vaccination in pregnancy and after pregnancy.
Each volunteer will participate for approximately 4 weeks including enrollment, vaccination, and completion of sample collection in 2 consecutive flu seasons. The Study has a total of 6 visits over 2 Flu seasons.
Study procedures:
Year One:
First Visit: Procedures during this visit are: Informed consent process, enrollment, study assessments, 20 ml blood draw, and vaccination.
2nd and 3rd visits: 20 ml blood will be obtained
Year Two:
First Visit: Study assessments, 20 ml blood draw, and vaccination. 2nd and 3rd visits: 20 ml blood will be obtained
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Philip Grant
- Phone Number: 6507239443
- Email: pmgrant@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18-49-year-old pregnant woman
- Willing and able to complete the informed consent process
- Availability for follow-up for the planned duration of the study with the expected delivery date more than 28 days after vaccination
- Acceptable medical history by review of inclusion/exclusion criteria
Exclusion Criteria:
- Prior off-study vaccination with seasonal influenza vaccine within three months of study vaccination
- Life-threatening reactions to previous influenza vaccinations
- Allergy to egg or egg products or to vaccine components including gentamicin, gelatin, or arginine.
- Active systemic or serious concurrent illness, including febrile illness on the day of vaccination
- History of immunodeficiency (including HIV infection)
- Known or suspected impairment of immunologic function; may include significant liver disease, diabetes mellitus treated with insulin or moderate to severe renal disease
- Chronic Hepatitis B or C.
- Recent or current use of immunosuppressive medication, including systemic glucocorticoids (corticosteroid nasal sprays and topical steroids are permissible). Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review by the investigator.
- Malignancy, other than squamous cell or basal cell skin cancer (includes solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia).
- Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator might jeopardize volunteer safety or compliance with the protocol.
- History of blood dyscrasias, renal disease, or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year
- Use of any anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin (except up to 325 mg. per day), Plavix, or Aggrenox will be reviewed by investigators to determine if study participation would affect the volunteer's safety or compliance with the protocol.
- Receipt of blood or blood products within the past 6 months or planned used during the study.
- A medical or psychiatric condition or occupational responsibilities that preclude participant compliance with the protocol
- Receipt of an inactivated vaccine 14 days prior to study enrollment, or planned vaccinations prior to completion of last annual study visit (~ 28 days after study vaccination)
- Receipt of a live, attenuated vaccine within 60 days prior to enrollment of planned vaccination prior to completion of last study visit (~ 28 days after study enrollment)
- Need for allergy immunization (that cannot be postponed) until after the last study visit.
- History of Guillain-Barre# syndrome
- Use of investigational agents within 30 days prior to enrollment or planned use during the study.
- Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment or donation of platelets within 2 weeks of enrollment or planned donation prior to completion of the last visit.
- Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Study Phase
Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
|
Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma HAI titer at Day 7 (year 1)
Time Frame: Day 7 (year 1)
|
HAI titer measures immune response to influenza vaccination
|
Day 7 (year 1)
|
Number of Participants With Related Adverse Events (year 1)
Time Frame: Day 28 (Year 1)
|
AEs to IIV
|
Day 28 (Year 1)
|
Number of Participants With Related Adverse Events (Year 2)
Time Frame: Day 28 (Year 2)
|
AEs to IIV
|
Day 28 (Year 2)
|
Plasma HAI titer at Day 7 (Year 2)
Time Frame: Day 7 (Year 2)
|
HAI titer measures immune response to influenza vaccination
|
Day 7 (Year 2)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Philip M Grant, Assistant Professor of Medicine (Infectious Diseases)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 50163
- 5U19AI057229-15 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Quadrivalent inactivated influenza vaccine (IIV)
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...WithdrawnInfluenzaUnited States
-
Kaiser PermanenteSanofi Pasteur, a Sanofi CompanyCompletedStroke | Pneumonia | Influenza | Congestive Heart Failure | Acute Myocardial Infarction | Lower Respiratory Tract InfectionUnited States
-
Emory UniversityRecruitingFollicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin LymphomaUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Sanofi Pasteur, a Sanofi CompanyCompletedInfluenza ImmunizationUnited States, Puerto Rico
-
Duke UniversityBoston Medical Center; Centers for Disease Control and Prevention; Children's...CompletedSafety | Birth Outcomes | Adverse Event Following ImmunisationUnited States
-
SeqirusCompleted
-
Vanderbilt University Medical CenterDuke University; Centers for Disease Control and Prevention; Children's Hospital...CompletedVaccine Adverse Reaction | Vaccine Reaction | Asthma | Influenza | Asthma in Children | WheezingUnited States